38.14
전일 마감가:
$37.43
열려 있는:
$37.69
하루 거래량:
1.31M
Relative Volume:
0.52
시가총액:
$9.81B
수익:
$2.08B
순이익/손실:
$466.92M
주가수익비율:
24.45
EPS:
1.56
순현금흐름:
$404.94M
1주 성능:
+7.12%
1개월 성능:
+3.88%
6개월 성능:
+33.77%
1년 성능:
+60.86%
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
EXEL
Exelixis Inc
|
38.16 | 9.81B | 2.08B | 466.92M | 404.94M | 1.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.12 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
601.52 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
615.94 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
253.10 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
250.42 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
2024-09-19 | 개시 | UBS | Neutral |
2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2023-12-19 | 개시 | BTIG Research | Buy |
2023-12-15 | 개시 | Citigroup | Buy |
2023-09-26 | 개시 | H.C. Wainwright | Buy |
2023-08-22 | 재확인 | Oppenheimer | Outperform |
2023-08-08 | 개시 | SVB Securities | Market Perform |
2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
2023-05-10 | 재개 | Piper Sandler | Overweight |
2023-03-09 | 개시 | Wells Fargo | Overweight |
2023-01-26 | 개시 | Credit Suisse | Outperform |
2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
2022-06-24 | 개시 | BMO Capital Markets | Outperform |
2021-11-19 | 개시 | Piper Sandler | Overweight |
2021-11-03 | 재개 | Jefferies | Buy |
2021-10-07 | 개시 | Jefferies | Buy |
2021-08-06 | 재확인 | H.C. Wainwright | Buy |
2021-06-15 | 개시 | H.C. Wainwright | Buy |
2021-05-18 | 재개 | Goldman | Sell |
2021-03-31 | 개시 | Credit Suisse | Outperform |
2021-03-12 | 개시 | Wolfe Research | Outperform |
2020-03-04 | 개시 | Barclays | Overweight |
2020-01-13 | 개시 | SunTrust | Buy |
2019-11-13 | 개시 | BofA/Merrill | Buy |
2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2018-09-17 | 개시 | Goldman | Neutral |
2018-09-10 | 개시 | Morgan Stanley | Underweight |
2018-05-11 | 재확인 | Needham | Buy |
2017-10-17 | 재확인 | Needham | Buy |
2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
2017-10-16 | 재확인 | SunTrust | Buy |
2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
2017-09-12 | 재확인 | Needham | Buy |
2017-07-14 | 개시 | SunTrust | Buy |
2017-03-31 | 개시 | Needham | Buy |
2017-03-16 | 개시 | Oppenheimer | Perform |
2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
2016-11-03 | 개시 | Deutsche Bank | Buy |
2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - The Globe and Mail
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts - Benzinga
Citizens JMP reiterates Exelixis stock with $41 target By Investing.com - Investing.com Canada
Citizens JMP reiterates Exelixis stock with $41 target - Investing.com
Exelixis, Inc. (NASDAQ:EXEL) Position Boosted by Summit Investment Advisors Inc. - MarketBeat
Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings - simplywall.st
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance
(EXEL) Investment Analysis - news.stocktradersdaily.com
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Prostate Cancer Pipeline Analysis and Clinical Trials - openPR.com
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis - openPR.com
Guggenheim maintains Exelixis stock with $42 target By Investing.com - Investing.com India
Guggenheim maintains Exelixis stock with $42 target - Investing.com
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Exelixis (EXEL) Gets a Buy from RBC Capital - The Globe and Mail
The Smartest Biotech Stocks to Buy With $50 - The Motley Fool
FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs - MarketBeat
Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - MSN
Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
New Age Alpha Advisors LLC Makes New $2.10 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis Launches Special Equity Award Program - TipRanks
(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN
What is Leerink Partnrs' Estimate for Exelixis Q1 Earnings? - MarketBeat
Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN
Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa
FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance
Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail
Exelixis stock holds $40 target post FDA nod - Investing.com
Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa
FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa
Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance
Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - Yahoo
Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India
Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):